Preview

Проблемы здоровья и экологии

Расширенный поиск

ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ (обзор литературы, часть I)

https://doi.org/10.51523/2708-6011.2009-6-4-2

Аннотация

В 4 частях обзора представлена информация о современной терапии острого коронарного синдрома (ОКС).

Об авторе

Д. П. Саливончик
Гомельский областной клинический кардиологический диспансер
Беларусь


Список литературы

1. ACC/AHA Guideline Update for the Management of Stable Angina and Non-ST-Segment Elevation Myocardial Infarction - 2002: Summary Article: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) // Circulation. - 2002. - Vol. 106. - P. 1893-1900.

2. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) / E. M. Antman [et al.] // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 211.

3. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) // Circulation. - 2006. - Vol. 113. - P. 156-175.

4. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative / T. J. Meine [et al.] // Am. Heart J. - 2005. - Vol. 149. - P. 1043-1049.

5. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the CUSTO-I experience Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries / M. Pfisterer [et al.] // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 634-640.

6. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial / P. A. Poole-Wilson [et al.] // Lancet. - 2003. - Vol. 362. - P. 7-13.

7. Routine use of oxygen in the treatment of myocardial infarction: Systematic review / M. Wijesinghe [et al.] // Heart. - 2009. - Vol. 95. - P. 198-202.

8. Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction / J. Am. Coll. Cardiol. - 2007. - Vol. 50. - P. 1-157.

9. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial / J. A. de Lemos [el al.] // J.A.M.A. - 2004. - Vol. 292. - P. 1307-1316.

10. Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial / S. Nissen [et al.] // J.A.M.A. - 2004. - Vol. 291. - P. 1071-1080.

11. Effects of Atorvastatine on Early Reccurents Ischemic Events in Acute Coronary Syndromes: The MIRACL Study: A Randomized Trial / G. G. Schwartz [et al.] // J.A.M.A. - 2001. - Vol. 285. - P. 1711-1718.

12. Hear Protection Collaborative Group MRC/BNF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individual: a randomized placebo-controlled trial / Lancet. - 2002. - Vol. 360. - P. 7-22.

13. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines / S M. Grundy [et al.] // Circulation. - 2004. - Vol. 110. - P. 227-239.

14. Intensive versus moderate lipid lowering with statins after acute coronary syndromes / C. P. Cannon [et al.] // N. Engl. J. Med. - 2004. - Vol. 350. - P. 1495-1504.

15. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy / C. P. Cannon [et al.] // J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P. 438-445.

16. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1349-1357.

17. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality / J. B. Muhlestein [et al.] // Am. J. Cardiol. - 2001. - Vol. 87. - P. 257-261.

18. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-Dose Atorvastatin vs. Usial-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial / T. R. Pedersen [et al.] // J.A.M.A. - 2005. - Vol. 294. - P. 2437-2445.

19. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) // Lancet. - 1994. - Vol. 344. - P. 1383-1389.

20. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels // N. Engl. J. Med. - 1998. - Vol. 339. - P. 1349-1357.

21. Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) / A. M. Gotto [et al.] // Circulation. - 2000. - Vol. 101. - P. 477-484.

22. Беленков, Ю. Н. Кардиология. Национальное руководство / Ю. Н. Беленков, Р. Г. Оганов. - М.: Геотар-Медиа, 2007. - 1232 с.

23. Antiatherotrombotic properties of statins: implications for cardiovascular event reduction // J.A.M.A. - 1998. - Vol. 279. - P. 1643-1650.

24. Benefits of Lipid Lowering on Vascular Reactivity in Patients with Coronary Artery Disease and Average Cholesterol Levels: A Mechanism for Reduction Clinical Events? / J. D. Cohen [et al.] // Am. Heart J. - 2000. - Vol. 139. - P. 734-738.

25. Effect of early treatment with statins on short-term clinical outcomes in acute coronary syndrome: a meta-analysis of randomized controlled trials / M. Briel [et al.] // J.A.M.A. - 2006. - Vol. - 295. - P. 2046-2056.

26. For the Asteroid Investigators. Effect of Very High-Intensity Statin Therapy in Regression of Coronary Atherosclerosis: The ASTEROID Trial / T. J. Nissen [et al.] // JAMA. - 2006. - Vol. 295. - P. 1556-1565.

27. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58050 patients with myocardial infarction // Lancet. - 1995. - Vol. 345. - P. 669-685.

28. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardio GISSI-3: effects of lisinopril and transdermal glyceril trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction // Lancet. - 1994. - Vol. 343. - P. 669-685.

29. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study / L. K. Newby [et al.] // Circulation. - 2001. - Vol. 103. - P. 1832-1837.

30. Beta blocade after myocardial infarction: systematic review and meta-regression analysis / N. Freemantle [et al.] // B.M.J. - 1999. - Vol. 32. - P. 634-640.

31. Dargie, H. J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial / H. J. Dargie // Lancet. - 2001. - Vol. 537. - P. 1385-1390.

32. Early intravenous then oral metoprolol in 45.852 patients with acute myocardial infarction: randomized placebo-controlled trial / Z. M. Chen [et al.] // Lancet. - 2005. - Vol. 366. - P. 1622-1632.

33. Mortality benefit of beta blockade in patients with acute coronary syndromes undergoing coronary intervention: pooled results from the Epic, Epilog, Epistent, Capture and Rapport trials / K. Ellis [et al.] // J. Interv. Cardiol. - 2003. - Vol. 16. - P. 299-305. 33а. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials / S. Yusuf [et al.] // J. Hypertens. - 1993. - Vol. 11, № 4. - Р. 61-73.

34. Danish Verapamil Infarction Trial (DAVIT) Study Group Cardiac event rates after acute myocardial infarction in patients treated with verapamil and trandolapril versus trandolapril alone / J.F. Hansen [et al.] // Am. J. Cardiol. - 1997. - Vol. 79. - P. 738-741.

35. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomized placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Trombolysis / W. E. Boden [et al.] // Lancet. - 2000. - Vol. 355. - P. 1751-1756.

36. Updata of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies / S. Yusuf [et al.] // Am. J. Cardiol. - 1991. - Vol. 67. - P. 1295-1297.

37. ACE Inhibitor Myocardial Infarction Collaborative Group Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials // Circulation. - 1998. - Vol. 97. - P. 2202-2212.

38. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years / P. Buch [et al.] // Eur. Heart J. - 2005. - Vol. 26. - P. 145-152.

39. Effect of an angiotensin-converting-enzime inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators / S. Yusuf [et al.] // N. Engl. J. Med. - 2000. - Vol. 342. - P. 145-153.

40. Long-term ACE-inhibitor therapy in heart failure or left-ventricular dysfunction: a systemic overview of data from individual patient / M. D. Flather [et al.] // Lancet. - 2000. - Vol. 355. - P. 1575-1581.

41. The BARI Investigators Seven-year outcome in the Bypass Angioplasty revascularization Investigation (BARI) by treatment and diabetic status // J. Am. Coll. Cardiol. - 2000. - Vol. 35. - P. 1122-1129.

42. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI-3 study / Z. Zuanetti [et al.] // Circulation. - 1997. - Vol. 96. - P. 4239-4245.

43. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review / K. K. Teo [et al.] // Lancet. - 2002. - Vol. 360. - P. 1037-1043.

44. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of there trials / G. R. Dagenais [et al.] // Lancet. - 2006. - Vol. 368. - P. 581-588.

45. Fox, K. M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study) / K.M. Fox // Lancet. - 2003. - Vol. 362. - P. 782-788.

46. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall program / M. A. Pfeffer [et al.] // Lancet. - 2003. - Vol. 362. - P. 759-766.

47. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction / B. Pitt [et al.] // N. Engl. J. Med. - 2003. - Vol. 348. - P. 1309-1321.

48. Randomized Aldactone Evaluation Study Investigators The Effect of spironolactone on morbidity and mortality in patients with severe heart failure / B. Pitt [et al.] // Engl. J. Med. - 1999. - Vol. 341. - P 709-717.

49. The Working Group on Neurocardiology Clinical outcome of patients treated with spinal cord stimulation for therapeutically refractory angina pectoris / I. A. Ten Vaarwerk [et al.] // Heart. - 1999. - Vol. 82. - P. 82-88.

50. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial / D. A. Morrow [et al.] // JAMA. - 2007. - Vol. 297. - P. 1775-1783.

51. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation / Jr. Holmes [et al.] // Circulation. - 1999. - Vol. 100. - P. 2067-2073.

52. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry / G. W. Stone [et al.] // J. Am. Col. Cardiol. - 2003. - Vol. 41. - P. 1940-1945.

53. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherotrombosis? Meta-analysis of randomized trials / P. M. Kearney [et al.] // B.M.J. - 2006. - Vol. 332. - P. 1302-1308.

54. For the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction / E. M. Antman [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1477-1488.

55. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) / W. Klein [et al.] // Circulation. - 1997. - Vol. 96. - P. 61-68.

56. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial / S. Yusuf [et al.] // J.A.M.A. - 2006. - Vol. 295. - P. 1519-1530.

57. Enoxaparion versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction / E. M. Antman [et al.] // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1477-1488.

58. Antitrombotics Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // B.M.J. - 2002. - Vol. 324. - P. 71-86.

59. Antithrombotic Therapy in Acute Coronary Syndromes Research Group Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial Circulation / M. Cohen [et al.] // Circulation. - 2004. - Vol. 89. - P. 81-88.

60. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease: Antithrombotic Therapy Consortium Inverstigators / R. C. Becker [et al.] // Am. Heart J. - 1999. - Vol. 137. - P. 59-71.

61. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease / E. M. Ohman [et al.] // J. Thromb. Thrombolysis. - 2005. - Vol. 19. - P. 11-19.

62. Hirsh, J. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy / J. Hirch, R. Raschke // Chest. - 2004. - Vol. 126. - P. 188-203.


Рецензия

Для цитирования:


Саливончик Д.П. ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ТЕРАПИИ (обзор литературы, часть I). Проблемы здоровья и экологии. 2009;(4):12-18. https://doi.org/10.51523/2708-6011.2009-6-4-2

For citation:


Salivonchik D.P. THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). Health and Ecology Issues. 2009;(4):12-18. (In Russ.) https://doi.org/10.51523/2708-6011.2009-6-4-2

Просмотров: 169


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.


ISSN 2220-0967 (Print)
ISSN 2708-6011 (Online)